Cargando…
SPCR-02 NEUROCOGNITIVE FUNCTION IN PATIENTS WITH LEPTOMENINGEAL METASTASIS TREATED WITH PROTON CRANIOSPINAL IRRADIATION
BACKGROUND: Proton craniospinal irradiation (pCSI) as a potential treatment for patients with solid tumor leptomeningeal metastasis (LM) is being assessed in a phase II randomized study comparing it with photon involved-field radiotherapy (RT). We report the preliminary results of prospective neuroc...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354226/ http://dx.doi.org/10.1093/noajnl/vdac078.077 |
_version_ | 1784763019254824960 |
---|---|
author | Correa, Denise Koch, Adrian Baser, Raymond Pentsova, Elena Wolden, Suzanne Imber, Brandon Boire, Adrienne Yang, Jonathan |
author_facet | Correa, Denise Koch, Adrian Baser, Raymond Pentsova, Elena Wolden, Suzanne Imber, Brandon Boire, Adrienne Yang, Jonathan |
author_sort | Correa, Denise |
collection | PubMed |
description | BACKGROUND: Proton craniospinal irradiation (pCSI) as a potential treatment for patients with solid tumor leptomeningeal metastasis (LM) is being assessed in a phase II randomized study comparing it with photon involved-field radiotherapy (RT). We report the preliminary results of prospective neurocognitive function in a subset of patients treated with pCSI. METHODS: Patients with LM and without evidence of CNS disease progression completed standardized neurocognitive tests of attention and working memory, executive function, and verbal memory at baseline (pre-pCSI), and 3 and 6 months post-pCSI. All patients received chemotherapy (baseline and follow up) and memantine (follow up). Means across the three timepoints were estimated for each neurocognitive test score using a linear mixed model (LMM) predicting the score by timepoint. Mean changes between pairs of timepoints were similarly estimated from the LMMs and tested for statistical significance using model-based contrasts. RESULTS: Baseline, 3-month and 6-month neurocognitive data were available for 12, 11, and 8 patients, respectively. Linear mixed model analyses showed a significant decline in graphomotor speed (Trails A, p=0.03), verbal learning (HVLT-R Total Learning, p<0.001), and verbal recognition memory (HVLT-R Discrimination, p=0.03) from baseline to 3 months post-pCSI, with scores remaining stable at 6 months post-pCSI. There was a significant decline in timed set-shifting (Trails B, p=0.04) from baseline to 6 months post-pCSI. There were no significant changes in attention and working memory over the follow-up period. CONCLUSION: Preliminary results in a subset of patients showed a decline in graphomotor speed and verbal memory at 3 months and executive function at 6 months post-pCSI, possibly related to the early adverse effects of RT. These results are overall consistent with findings in other populations treated with whole-brain RT. However, there was no change in attention and working memory and most cognitive domains remained stable at six months with pCSI. |
format | Online Article Text |
id | pubmed-9354226 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-93542262022-08-09 SPCR-02 NEUROCOGNITIVE FUNCTION IN PATIENTS WITH LEPTOMENINGEAL METASTASIS TREATED WITH PROTON CRANIOSPINAL IRRADIATION Correa, Denise Koch, Adrian Baser, Raymond Pentsova, Elena Wolden, Suzanne Imber, Brandon Boire, Adrienne Yang, Jonathan Neurooncol Adv Supplement Abstracts BACKGROUND: Proton craniospinal irradiation (pCSI) as a potential treatment for patients with solid tumor leptomeningeal metastasis (LM) is being assessed in a phase II randomized study comparing it with photon involved-field radiotherapy (RT). We report the preliminary results of prospective neurocognitive function in a subset of patients treated with pCSI. METHODS: Patients with LM and without evidence of CNS disease progression completed standardized neurocognitive tests of attention and working memory, executive function, and verbal memory at baseline (pre-pCSI), and 3 and 6 months post-pCSI. All patients received chemotherapy (baseline and follow up) and memantine (follow up). Means across the three timepoints were estimated for each neurocognitive test score using a linear mixed model (LMM) predicting the score by timepoint. Mean changes between pairs of timepoints were similarly estimated from the LMMs and tested for statistical significance using model-based contrasts. RESULTS: Baseline, 3-month and 6-month neurocognitive data were available for 12, 11, and 8 patients, respectively. Linear mixed model analyses showed a significant decline in graphomotor speed (Trails A, p=0.03), verbal learning (HVLT-R Total Learning, p<0.001), and verbal recognition memory (HVLT-R Discrimination, p=0.03) from baseline to 3 months post-pCSI, with scores remaining stable at 6 months post-pCSI. There was a significant decline in timed set-shifting (Trails B, p=0.04) from baseline to 6 months post-pCSI. There were no significant changes in attention and working memory over the follow-up period. CONCLUSION: Preliminary results in a subset of patients showed a decline in graphomotor speed and verbal memory at 3 months and executive function at 6 months post-pCSI, possibly related to the early adverse effects of RT. These results are overall consistent with findings in other populations treated with whole-brain RT. However, there was no change in attention and working memory and most cognitive domains remained stable at six months with pCSI. Oxford University Press 2022-08-05 /pmc/articles/PMC9354226/ http://dx.doi.org/10.1093/noajnl/vdac078.077 Text en © The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Supplement Abstracts Correa, Denise Koch, Adrian Baser, Raymond Pentsova, Elena Wolden, Suzanne Imber, Brandon Boire, Adrienne Yang, Jonathan SPCR-02 NEUROCOGNITIVE FUNCTION IN PATIENTS WITH LEPTOMENINGEAL METASTASIS TREATED WITH PROTON CRANIOSPINAL IRRADIATION |
title | SPCR-02 NEUROCOGNITIVE FUNCTION IN PATIENTS WITH LEPTOMENINGEAL METASTASIS TREATED WITH PROTON CRANIOSPINAL IRRADIATION |
title_full | SPCR-02 NEUROCOGNITIVE FUNCTION IN PATIENTS WITH LEPTOMENINGEAL METASTASIS TREATED WITH PROTON CRANIOSPINAL IRRADIATION |
title_fullStr | SPCR-02 NEUROCOGNITIVE FUNCTION IN PATIENTS WITH LEPTOMENINGEAL METASTASIS TREATED WITH PROTON CRANIOSPINAL IRRADIATION |
title_full_unstemmed | SPCR-02 NEUROCOGNITIVE FUNCTION IN PATIENTS WITH LEPTOMENINGEAL METASTASIS TREATED WITH PROTON CRANIOSPINAL IRRADIATION |
title_short | SPCR-02 NEUROCOGNITIVE FUNCTION IN PATIENTS WITH LEPTOMENINGEAL METASTASIS TREATED WITH PROTON CRANIOSPINAL IRRADIATION |
title_sort | spcr-02 neurocognitive function in patients with leptomeningeal metastasis treated with proton craniospinal irradiation |
topic | Supplement Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354226/ http://dx.doi.org/10.1093/noajnl/vdac078.077 |
work_keys_str_mv | AT correadenise spcr02neurocognitivefunctioninpatientswithleptomeningealmetastasistreatedwithprotoncraniospinalirradiation AT kochadrian spcr02neurocognitivefunctioninpatientswithleptomeningealmetastasistreatedwithprotoncraniospinalirradiation AT baserraymond spcr02neurocognitivefunctioninpatientswithleptomeningealmetastasistreatedwithprotoncraniospinalirradiation AT pentsovaelena spcr02neurocognitivefunctioninpatientswithleptomeningealmetastasistreatedwithprotoncraniospinalirradiation AT woldensuzanne spcr02neurocognitivefunctioninpatientswithleptomeningealmetastasistreatedwithprotoncraniospinalirradiation AT imberbrandon spcr02neurocognitivefunctioninpatientswithleptomeningealmetastasistreatedwithprotoncraniospinalirradiation AT boireadrienne spcr02neurocognitivefunctioninpatientswithleptomeningealmetastasistreatedwithprotoncraniospinalirradiation AT yangjonathan spcr02neurocognitivefunctioninpatientswithleptomeningealmetastasistreatedwithprotoncraniospinalirradiation |